Price Disclosure Reductions for 2018 April Cycle
Page last updated: 7 March 2018
Please note: The information on this page has been updated following amendments to the National Health (Weighted average disclosed price – April 2018 reduction day) Determination 2018. Amendments were made to reflect changes to the price disclosure requirements under Division 3B of the National Health Act 1953 by the National Health Amendment (Pharmaceutical Benefits—Budget and Other Measures) Act 2018 that received Royal Assent on 20 February 2018.
This summary only includes medicines taking a price disclosure reduction on 1 April 2018. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) as amended and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations) in force currently.
The outcomes below show percentage (%) price differences and ex‑manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.
Flow-on Reductions for F2 Combination Items
Responsible persons with a brand of an F2 combination item should note that:
- if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2018 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
- if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.
Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs late January 2018.
Legal Determination & Next Steps
The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the legislation.gov.au website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2017 PBS approved ex‑manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable). Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 30 September 2017 will also take the reduction on 1 April 2018 under section 99ADHA of the Act.
An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 19 January 2018.
Indicative prices for 1 April 2018 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2018. Subscribe to PBS News to receive notice when they become available.
Final prices for 1 April 2018 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from mid-March 2018.
| Legal Instrument Drug (drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) |
Legal Instrument MoA | Legal Instrument Form | Average AEMP ($) |
WAPD (%) across a drug/MoA |
WADP - potential April '18 PBS Price (AEMP) ($) per pharmaceutical item |
October '17 AEMP ($) |
Percentage difference between October '17 and April '18 PBS prices (AEMP) (%) per pharmaceutical item |
Calculations based on: OWAPD = all brand data GWAPD = originator brand data removed for at least one pharmaceutical item No originator brand determined Does not meet 30 month clock |
|---|---|---|---|---|---|---|---|---|
| [Average AEMP minus WAPD = WADP] | [Difference between October '17 AEMP & WADP = % Difference] | |||||||
| Aripiprazole | Oral | Tablet 10 mg | 98.40 | 10.23% | 88.33 | 98.40 | 10.23% | Does not meet 30 month clock |
| Aripiprazole | Oral | Tablet 15 mg | 139.63 | 10.23% | 125.35 | 139.63 | 10.23% | Does not meet 30 month clock |
| Aripiprazole | Oral | Tablet 20 mg | 169.97 | 10.23% | 152.58 | 169.97 | 10.23% | Does not meet 30 month clock |
| Aripiprazole | Oral | Tablet 30 mg | 207.12 | 10.23% | 185.93 | 207.12 | 10.23% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 10 mg (as hydrochloride) | 73.02 | 22.39% | 56.67 | 73.02 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 100 mg (as hydrochloride) | 94.92 | 22.39% | 73.67 | 94.92 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 18 mg (as hydrochloride) | 73.02 | 22.39% | 56.67 | 73.02 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 25 mg (as hydrochloride) | 73.02 | 22.39% | 56.67 | 73.02 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 40 mg (as hydrochloride) | 73.02 | 22.39% | 56.67 | 73.02 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 60 mg (as hydrochloride) | 73.02 | 22.39% | 56.67 | 73.02 | 22.39% | Does not meet 30 month clock |
| Atomoxetine | Oral | Capsule 80 mg (as hydrochloride) | 94.92 | 22.39% | 73.67 | 94.92 | 22.39% | Does not meet 30 month clock |
| Azacitidine | Injection | Powder for injection 100 mg | 369.44 | 14.11% | 317.31 | 369.44 | 14.11% | Does not meet 30 month clock |
| Capecitabine | Oral | Tablet 150 mg | 20.89 | 39.82% | 12.57 | 15.07 | 16.59% | GWAPD |
| Capecitabine | Oral | Tablet 500 mg | 129.51 | 39.82% | 77.94 | 93.40 | 16.55% | GWAPD |
| Cefepime | Injection | Powder for injection 1 g (as hydrochloride) | 6.35 | 41.32% | 3.73 | 6.35 | 41.26% | No originator brand determined |
| Cefepime | Injection | Powder for injection 2 g (as hydrochloride) | 11.02 | 41.32% | 6.47 | 11.02 | 41.29% | No originator brand determined |
| Celecoxib | Oral | Capsule 100 mg | 6.45 | 18.90% | 5.23 | 6.45 | 18.91% | Does not meet 30 month clock |
| Celecoxib | Oral | Capsule 200 mg | 6.45 | 18.90% | 5.23 | 6.45 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (extended release) 100 mg (as succinate) | 16.29 | 18.88% | 13.21 | 16.29 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (extended release) 50 mg (as succinate) | 13.27 | 18.88% | 10.76 | 13.27 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (modified release) 100 mg | 16.29 | 18.88% | 13.21 | 16.29 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (modified release) 100 mg (as benzoate) | 16.29 | 18.88% | 13.21 | 16.29 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (modified release) 50 mg | 13.27 | 18.88% | 10.76 | 13.27 | 18.91% | Does not meet 30 month clock |
| Desvenlafaxine | Oral | Tablet (modified release) 50 mg (as benzoate) | 13.27 | 18.88% | 10.76 | 13.27 | 18.91% | Does not meet 30 month clock |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | 264.80 | 15.62% | 223.44 | 264.80 | 15.62% | OWAPD |
| Doxorubicin - pegylated liposomal | Injection | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 50 mg in 25 mL | 630.47 | 15.62% | 531.99 | 630.47 | 15.62% | OWAPD |
| Entecavir | Oral | Tablet 0.5 mg (as monohydrate) | 306.68 | 23.49% | 234.64 | 306.68 | 23.49% | Does not meet 30 month clock |
| Entecavir | Oral | Tablet 1 mg (as monohydrate) | 498.75 | 23.49% | 381.59 | 498.75 | 23.49% | Does not meet 30 month clock |
| Esomeprazole | Oral | Capsule (enteric) 20 mg (as magnesium) | 10.21 | 42.46% | 5.87 | 9.14 | 35.78% | GWAPD |
| Esomeprazole | Oral | Capsule (enteric) 40 mg (as magnesium) | 17.32 | 42.46% | 9.97 | 15.50 | 35.68% | GWAPD |
| Esomeprazole | Oral | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | 10.21 | 42.46% | 5.87 | 9.14 | 35.78% | GWAPD |
| Esomeprazole | Oral | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | 17.32 | 42.46% | 9.97 | 15.50 | 35.68% | GWAPD |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL | 20.00 | 32.88% | 13.42 | 20.00 | 32.90% | No originator brand determined |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL | 8.00 | 32.88% | 5.37 | 8.00 | 32.88% | No originator brand determined |
| Irinotecan | Injection | I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL | 100.00 | 32.88% | 67.12 | 100.00 | 32.88% | No originator brand determined |
| Lamivudine* | Oral | Oral solution 5 mg per mL, 240 mL | 45.25 | 44.22% | 25.24 | 45.25 | 44.22% | GWAPD |
| Lamivudine with zidovudine | Oral | Tablet 150 mg-300 mg | 275.68 | 36.72% | 174.45 | 275.68 | 36.72% | GWAPD |
| Metoprolol succinate | Oral | Tablet 190 mg (controlled release) | 56.62 | 23.48% | 43.33 | 56.62 | 23.47% | GWAPD |
| Metoprolol succinate | Oral | Tablet 23.75 mg (controlled release) | 7.68 | 23.48% | 5.88 | 7.68 | 23.44% | GWAPD |
| Metoprolol succinate | Oral | Tablet 47.5 mg (controlled release) | 36.25 | 23.48% | 27.74 | 36.25 | 23.48% | GWAPD |
| Metoprolol succinate | Oral | Tablet 95 mg (controlled release) | 45.30 | 23.48% | 34.66 | 45.30 | 23.49% | GWAPD |
| Naloxone | Injection | Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe | 58.56 | 26.37% | 43.12 | 58.56 | 26.37% | Does not meet 30 month clock |
| Naloxone | Injection | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | 66.40 | 26.37% | 48.89 | 66.40 | 26.37% | Does not meet 30 month clock |
| Olmesartan | Oral | Tablet containing olmesartan medoxomil 20 mg | 7.43 | 24.22% | 5.63 | 7.43 | 24.23% | Does not meet 30 month clock |
| Olmesartan | Oral | Tablet containing olmesartan medoxomil 40 mg | 15.76 | 24.22% | 11.94 | 15.76 | 24.24% | Does not meet 30 month clock |
| Pemetrexed | Injection | Powder for I.V. infusion 1 g (as disodium) | 476.07 | 72.41% | 131.35 | 208.08 | 36.88% | Does not meet 30 month clock |
| Pemetrexed | Injection | Powder for I.V. infusion 100 mg (as disodium) | 47.61 | 72.41% | 13.14 | 20.81 | 36.86% | Does not meet 30 month clock |
| Pemetrexed | Injection | Powder for I.V. infusion 500 mg (as disodium) | 238.03 | 72.41% | 65.67 | 104.04 | 36.88% | Does not meet 30 month clock |
| Sildenafil | Oral | Tablet 20 mg (as citrate) | 319.72 | 20.46% | 254.31 | 319.72 | 20.46% | GWAPD |
| Telmisartan | Oral | Tablet 40 mg | 2.50 | 34.04% | 1.65 | 1.94 | 14.95% | GWAPD |
| Telmisartan | Oral | Tablet 80 mg | 7.24 | 34.04% | 4.78 | 5.61 | 14.80% | GWAPD |
| Valsartan | Oral | Tablet 160 mg | 10.63 | 19.69% | 8.54 | 10.63 | 19.66% | GWAPD |
| Valsartan | Oral | Tablet 320 mg | 13.63 | 19.69% | 10.95 | 13.63 | 19.66% | GWAPD |
| Valsartan | Oral | Tablet 40 mg | 5.68 | 19.69% | 4.56 | 5.68 | 19.72% | GWAPD |
| Valsartan | Oral | Tablet 80 mg | 8.28 | 19.69% | 6.65 | 8.28 | 19.69% | GWAPD |
| Voriconazole | Oral | Tablet 200 mg | 1,756.57 | 27.35% | 1,276.15 | 1,461.99 | 12.71% | Does not meet 30 month clock |
| Voriconazole | Oral | Tablet 50 mg | 439.14 | 27.35% | 319.04 | 365.50 | 12.71% | Does not meet 30 month clock |
| Zoledronic acid | Injection | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | 245.33 | 29.12% | 173.89 | 245.33 | 29.12% | Does not meet 30 month clock |
| Zoledronic acid | Injection | Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL | 245.33 | 29.12% | 173.89 | 245.33 | 29.12% | Does not meet 30 month clock |
| Zoledronic acid | Injection | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | 328.46 | 29.12% | 232.81 | 328.46 | 29.12% | Does not meet 30 month clock |
